Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor

@article{LenoxSmith2008VenlafaxineER,
  title={Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor},
  author={Alan J. Lenox-Smith and Qin Jiang},
  journal={International Clinical Psychopharmacology},
  year={2008},
  volume={23},
  pages={113-119}
}
Findings from the National Institute of Mental Health's Sequenced Treatment Alternatives to Relieve Depression trial indicate that approximately 50% of patients with major depressive disorder do not experience a treatment response after adequate first-line treatment with a selective serotonin reuptake inhibitor (SSRI). This study was designed to test the hypothesis that, after treatment failure with an SSRI, switching to venlafaxine extended release (ER) would offer advantages over switching to… 
Tolerability of High-Dose Venlafaxine After Switch From Escitalopram in Nonresponding Patients With Major Depressive Disorder
TLDR
In patients receiving high-dose VF, a significant improvement of depressive symptomatology was observed, and most ADRs decreased during the course of treatment, even in patients above the therapeutic reference range.
Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder
TLDR
Vortioxetine is a well tolerated treatment, showing statistically lower withdrawal rates due to AEs compared with other antidepressants, and is a relevant therapeutic alternative in patients experiencing inadequate response to prior SSRI or SNRI therapy.
Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity
TLDR
It is demonstrated that venlafaxine may be superior to SSRIs in achieving remission in both mild/moderate and severely depressed patients.
Double-blind switch study of vilazodone in the treatment of major depressive disorder
TLDR
Evaluated patients with major depressive disorder who are unresponsive or only partially responsive to a trial of citalopram were switched to vilazodone and both groups showed decreases in all outcome measures, but there were no significant differences between groups.
Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder
Venlafaxine or a second SSRI: Switching after treatment failure with an SSRI among depressed inpatients: A retrospective analysis
Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies
TLDR
This meta-analysis includes all published, randomized, double-blind, head-to-head trials, which compared venlafaxine and an SSRI in the treatment of MDD in adults, and shows that venl Lafaxine was superior to SSRIs in achieving remission and response.
Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study
TLDR
Vortioxetine was at least as efficacious as venlafaxine XR and was safe and better tolerated than venl Rafael XR, and response and remission rates demonstrated similar improvement.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 24 REFERENCES
Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study
TLDR
It is suggested that venlafaxine extended release may be more effective than the conventional antidepressants used in this study when treating depressed patients who do not tolerate or respond adequately to treatment with a conventional antidepressant.
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
TLDR
Remission rates were significantly higher with venlafaxine than with an SSRI and the difference between SSRIs and placebo reached significance at week 4, and were not dependent on any one study or the definition of remission.
Venlafaxine and paroxetine in treatment-resistant depression
TLDR
Venlafaxine showed some evidence of superiority to paroxetine in this difficult-to-treat patient population of patients with non-chronic treatment-resistant depression.
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials.
  • M. Keller
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2000
TLDR
Data published over the last decade suggest that citalopram is superior to placebo in the treatment of depression, has efficacy similar to that of the tricyclic and tetracyclic antidepressants and to other SSRIs, and is safe and well tolerated in the therapeutic dose range of 20 to 60 mg/day.
Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices.
TLDR
Clinicians select different next-step strategies when patients are nonresponders versus when patients is partial responders or relapsers, and switching to a non-SSRI agent was the most frequently chosen option for non responders to an adequate trial of SSRI therapy.
Treatment strategy in depression
TLDR
The results indicate that selective reuptake inhibitors are not an effective alternative for non‐responders to other cyclic antidepressants and that non‐ responders to ‘nor‐adrenergic’ antidepressants do not appear to have much chance of responding to “serotonergic” antidepressants and vice versa.
Treatment strategy in depression
TLDR
It is concluded that MAO inhibitors such as tranylcypromine are an effective alternative to ECT and lithium in patients with major depression who have failed to respond to cyclic antidepressants.
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
TLDR
The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials.
Citalopram in Depression—Meta‐analysis of Intended and Unintended Effects
TLDR
In conclusion, citalopram has been found to be a non-sedating antidepressant which is well accepted by the patients due to its lack of unintended effects.
...
1
2
3
...